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Nucleotide sequences have been obtained for RNA segments encoding the PB2, PB1, PA, NP, M1, M2, NS1, and 
NS2 proteins of the influenza A/Ann Arbor/6/60 (H2N2) wild-type (wt) virus and its cold-adapted (ca) derivative that 
has been used for preparing investigational live attenuated vaccines. Twenty-four nucleotida differences between the 
ca and wt viruses were detected, of which 11 were deduced to code for amino acid substitutions in the ca virus proteins. 
One amino acid substitution each was predicted for the PB2, M2, and NS1 proteins. Two amino acid substitutions 
were predicted for the NP and the PA proteins. Four substitutions were predicted for the PB1 protein. The biological 
significance of mutations in the PB2, PB1, PA, and M2 genes of the ca virus is suggested by currently available genetic 
data, a comparison with other available influenza gene sequences, and the nature of the predicted amino acid changes. 
In addition, the sequence data confirm the close evolutionary relationship between the genomes of influenza A (H2N2) 
and influenza A (H3N2) viruses. © 1988Academlc Press, Inc. 
INTRODUCTION 
One approach for producing live attenuated influ- 
enza A vaccines is attenuation of new epidemic vari- 
ants by reassortment with a cold-adapted (ca) temper- 
ature-sensitive (ts) mutant donor strain, A/Ann Arbor/6/ 
60 (H2N2)(Maassab etaL, 1972; Kendal eta/., 1981; 
Cox, 1986). This prototype ca virus was derived by se- 
rial passage of the wild-type (wt) A/Ann Arbor/6/60 vi- 
rus at successively lower temperatures until virus 
emerged that could replicate efficiently at 25 ° (Maas- 
sab, 1967; Kendal eta/., 1981). Although the ca A/Ann 
Arbor/6/60 donor virus has not been thoroughly tested 
in human volunteers, it is attenuated in a ferret model 
system (Maassab et aL, 1982). Reassortant viruses 
that received the hemagglutinin (HA) and neuramini- 
dase (NA) genes from a new H1 N1 or H3N2 epidemic 
variant virus and five or six of their other genes from 
the ca A/Ann Arbor/6/60 parent have been examined 
extensively. These ca reassortants had similar ca and 
ts properties in cell culture, and were attenuated, im- 
munogenic, and phenotypically stable when adminis- 
tered to ferrets (Maassab et aL, 1982). They also were 
attenuated, immunogenic, and protective in challenge 
and field studies in humans (Davenport eta/ . ,  1977; 
Hrabar etal.,  1977; Murphy etaL, 1979, 1980, 1981, 
1982; Lazar et al., 1 980; Reeve eta/., 1 980b; Mortiz et 
al., 1980; Van Voorthuizen et aL, 1981; Cate and 
1 To whom requests for reprints should be addressed. 
Couch, 1982; Wright et a/., 1982; Clements et aL, 
1983; Belshe and Van Voris, 1 984; Couch etaL, 1 986). 
It has not yet been determined if live ca viruses pro- 
vide the theoretical benefits proposed for attenuated 
influenza vaccine (Stuart-Harris, 1980) or can be ap- 
plied for influenza control on a large scale. Promising 
vaccine trials, however, have justified parallel labora- 
tory studies to examine the molecular basis for attenu- 
ation and the genetic stability of the ca A/Ann Arbor/6/ 
60 mutant. It was proposed previously that the re- 
stricted gene composition of ca reassortant viruses 
was advantageous for producing live attenuated influ- 
enza vaccines because viruses with five or six internal 
genes of the ca donor strain would be expected to have 
more uniform biological and attenuation properties 
(Cox et al., 1979). Genetic stability of several vaccine 
strains having five or six genes from the ca parent was 
examined before and after replication in humans using 
T1 oligonucleotide mapping, and relative genetic sta- 
bility was demonstrated (Cox and Kendat, 1 984). To di- 
rectly identify genes of the ca donor strain A/Ann Arbor/ 
6/60 that contained mutations, we used a variety of 
biochemical techniques to compare RNAs and pro- 
teins of the ca and wt viruses. These procedures de- 
tected differences in each of the eight RNA segments 
of the ca mutant compared with the wt parent (Cox et 
aL, 1986). Here we present the entire nucleotide se- 
quences for the six genes of the wt and ca A/Ann Ar- 
bor/6/60 viruses that are relevant for producing reas- 
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sortant candidate vaccine viruses. Knowledge of these 
nucteotide sequences will be useful for monitoring ge- 
netic stability of attenuated vaccines during production 
and use as welt as for understanding the molecular 
mechanism(s) of viral attenuation. 
MATERIALS AND METHODS 
Viruses and viral RNA 
The A/Ann Arbor/6/60 wt virus and the derivation of 
the ca A/Ann Arbor/6/60 mutant have been described 
(Maassab, 1967; Kendal et al., 1981). No further 
plaque purifications or end-point dilutions were per- 
formed. Viruses were propagated at a low multiplicity 
of infection in the altantoic cavity of 10-day-old embryo- 
nated eggs at 34 ° and purified as described pre- 
viously (Cox and Kendal, 1984). Ca mutant and wt virus 
preparations used throughout this study for sequenc- 
ing varied by no more than three egg passages for the 
mutant (E 4 tO Ee) and by five egg passages for the wt 
(E28 to E32 ). Sequencing of RNA obtained from these 
different passage levels of the same virus revealed no 
sequence differences. Virion RNA was extracted as de- 
scribed previously (Palese and Schulman, 1976) and 
dissolved to yield approximately 1 mg/ml. 
Nucleotide sequence analysis of viral RNA 
Sequence analysis was accomplished using either 
of two variations of the dideoxy chain termination 
method (Sanger et aL, 1977). The incorporative 
method was performed essentially as described pre- 
viously (Air, 1979; Cox et  al., 1986). Each 5.5-#1 reac- 
tion mixture contained 45 mM of Tris-HCI (pH 8.3), 45 
mMof KCI, 4.5 mMof MgCl2, 9 mMof DTT, 1.4 #Mof  
dATP, 12.5 #Ci of [~-32p]-dATP (NEN Research Prod- 
ucts, Boston, MA), 2 45.5 #M of dGTP (9.1 #M of dGTP 
for the G reaction), 4.5 #M of dCTP (9.1 #M of dCTP for 
the C reaction), 45.5 #M of d-l-I-P (9.1 #M of dTTP for 
the T reaction), 50-100 ng of RNA, 1-5 ng of primer, 3 
units of reverse transcriptase (Life Sciences, Inc., St. 
Petersburg, FL), and 1-5 #M of ddATP, ddCTP, dd- 
GTP, or ddTTP. Reaction mixtures were incubated at 
37 ° for 30 min, after which 1 #1 of a chase mixture con- 
taining 1 mM each of dATP, dCTP, dGTP, and dTTP 
was added, and the incubation was continued at 37 ° 
for 30 min. Terminal deoxynucleotidyl transferase 
(Bethesda Research Laboratories, Gaithersburg, MD) 
was added to the chase mixture when necessary to 
resolve sequence abiguities (DeBorde et aL, 1986). 
2 Use of trade names and commercial sources is for identification 
only and does not imply endorsement by the U.S. Public Health Ser- 
vice or the Department of Health and Human Services. 
The reaction was stopped by adding 1 #1 of 0.1 M 
EDTA, and samples were dried and finally dissolved in 
5 #1 of a formamide dye mixture. 
The second method used 5'-7-32p-labeled synthetic 
oligodeoxynucleotides for priming the reaction. Each 
5-#1 reaction mixture contained 50 mM of Tris-HCI (pH 
8.3), 50 mMof KCI, 5 mMof MgCI~, 10 mMof DTT, 50 
mM each of dATP, dCTP, dGTP, and dTTP, 3.75 units 
of human placenta RNase inhibitor (Promega Biotec, 
Madison, WI), 200 ng of RNA, 1-5 ng primer, 3 units 
of reverse transcriptase, and approximately 10 #M of 
ddATP, ddCTP, ddGTP, or ddq-FP. After incubation at 
42 ° for 30 min, reaction products were analyzed on 6 
and 8% polyacrylamide gels containing 100 mM of 
Tris-borate (pH 8.3), 5 mMof EDTA, and 8.3 Mof urea. 
Oligonucteotide primers were synthesized either by 
C. W. Naeve (St. Jude Children's Hospital) or by B. Hol- 
Ioway (Centers for Disease Control) on an Applied Bio- 
systems Model 380A DNA synthesizer using the solid- 
phase phosphoramidite method. Primers used were as 
follows: the universal primer d(AGCAAAAGCAGG), 
PB2-28 d(ATGGAAAGAATAAAA), PB2-102 d(GGAC- 
CATATGGC), PB2-225 d(GACAAGAGGATA), PB2-451 
d(CGCCGAAGAGTT), PB2-698 d(CAAGCAGTGTAT), 
PB2-905 d(GGATGGTGGACA) PB2-946 d(GCTGTG- 
GAAATATGC), PB2-1125 d(TGGGAAAAGGGC), PB2- 
1349 d(ATGCTAAAGTGC), PB2-t570 d(CCTGAG- 
GAGGTC), PB2-1780 d(CCTAAGGCCATT), PB2-2085 
d(GGAGTCAGCTGT), PB2-2190 d(GGCTAATGTACT), 
PB 1 - 13 d(CAAACCATFI-GAATGG), PB 1-208 d(GGAG- 
CGCCCCAACT), PB1-400 d(CGTCAGACCTATGA), 
PB 1-601 d(GACAACATGACCAAGA), PB 1-745 d(AA- 
TGCAACACCCGGGA), PB1-909 d(CACAGAGCT- 
TTC), PB1-1000 d(ACAAGAAATCAACCT), PB1-1105 
d(AGCATGAAGCTCCGAA), PB1-1375 d(GTGAATG- 
CACCA), PB1-1600 d(GGAGTAACAGTG) PB1-1801 
d(GATGGAGGACCAAACT), PB1-2046 d(CCTCAACA- 
CAAG), PB1-2209 d(GAC-i-i-CGAGTCTGGA), PA-158 
d(GCTTCATGTATT), PA-226 d(CCAAATGCACTT), 
PA-452 d(CACACATCCACA), PA-681 d(CCCGCC- 
GAACTT), PA-876 d(GATGGATGCTTT), PA-1112 
d(CGAGTCAGCTAA), PA-1339 d(GCAAGCATGAGA), 
PA-1540 d(AAAGGAAGATCTCA), PA-1601 d(CTCT- 
CACTGACC), PA-1789 d(CTCCAACAAATC), PA-1800 
d(CGAGAGTATGAT), PA-1900 d(AAAGGAGTGGAA- 
GAA), PA-2009 d(CAAGAAAACTGC), PA-2026 d(GTC- 
GTTCAGGCT), PA-2080 d(CTATATGAAGCAATT), 
NP-160 d(q-i-CTACATCCAA), NP-202 d(GAGGGGC- 
GACUG), NP-397 d(CGAATCTGGCGC), NP-643 
d(GGGATCAATGAT), NP-888 d(TGGACCTGCCGT), 
N P- 1015 d(CACAAGAGTCAG), N P- 1285 d(GTGCAAA- 
GAAACCTTC), M-239 d(CGAGGACTGCAG), M-438 
d(GCTGACTCCCAG), M-719 d(GATCTTCq-I-GAAAAT- 
TTG), M-895 d(GAGGGCCTTCTA), NS-207 d(G- 
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GAAAGCAGATAGTG), NS-384 d(GACCAGGCAATC), 
NS-597 d(ACAG-i-FCGAGTC) and NS-742 d(GAAGT- 
GAGACAC). Primer numbers correspond to the posi- 
tion (in the mRNA sense sequence) of the first nucleo- 
tide in the primer. 
Nucleotide sequence analysis of mRNA 
The nucleotide sequence of the first 25-40 nucleo- 
tide~ of the 3' region of each gene was obtained using 
synthetic primers complementary to viral mRNA. Con- 
fluent MDCK cells were infected at a multiplicity of ap- 
proximately 2 PFU/cell and harvested by scraping at 
6 or 8 hr postinfection for the wt and mutant viruses, 
respectively. Cells were washed once in ice-cold phos- 
phate-buffered saline and lysed in a buffer containing 
5.8 M of guanidinium-hydrochloride, 50 mM of Tris- 
HCI (pH 7.6), 10 mM of EDTA, 2% sodium lauryl sar- 
kosinate, and 1%/~-mercaptoethanol prepared as de- 
scribed previously (Maniatis et aL, 1982). RNA isolated 
by centrifugation through a CsCI cushion (Maniatis et 
aL, 1982) was suspended in 20 mMTris-HCI (pH 7.4), 
1 mM EDTA and 0.1% sodium dodecyl sulfate (SDS), 
ethanol precipitated, and stored at -70 ° in sterile dis- 
tilled water. Approximately 50 #g of total RNAwas used 
in each incorporative sequencing reaction carried out 
as described above. Primers used were as follows: 
mNS-77t d(ATGGGGCATCACCTAGTT), mM-911 
d(ACATCTTCAAGTCTCTGT), mNP-1433 d(CGACG- 
GATGCTCTGA-i-i-T), mPA-2151 d(GCTTTq-i-CAGCAA- 
GCTOGACAATC), mPB1-2233 d(GAGGATCTCCA- 
GTATAAG), and mPB2-2253 d(GTTAGTATCTOGO- 
GAGTG). Primer numbers correspond to the position 
(in the virion sense RNA sequence) of the first nucleo- 
tide in the primer. 
Computer analysis 
Nucleotide sequences were stored and manipulated 
on a Digital Equipment Corp. VAX computer using ver- 
sion 5 of the sequence analysis software package of 
the University of Wisconsin Genetics Computer Group 
(Devereaux et aL, 1984). 
RESULTS 
Nucleotide sequences of the NS1, NS2, M1, M2, 
NP, PA, PB1, and PB2 genes of the A/Ann Arbor/6/60 
mutant and wt viruses were determined directly using 
the dideoxy chain termination method (Sanger et aL, 
1977) modified for sequencing from virion RNA (Air, 
1979). Bands in two lanes of the reaction were ob- 
served occasionally at a single nucleotide position. 
(These postions are indicated by asterisks in the fig- 
ures). The darkest band was read as the correct nucle- 
otide. In addition, the NS and M genes of the wt virus 
were cloned into pBR322 and sequenced using the 
chemical sequencing method of Maxam and Gilbert 
(1980). Results using the chemical method were identi- 
cal to those using the dideoxy chain termination 
method (data not shown). The sequences of the HA 
and NA genes of the A/Ann Arbor/6/60 viruses were 
not determined because they are irrelevant for produc- 
ing reassortant candidate vaccine strains. Sequences 
of H2N2 virus genes have been published previously 
for only the NS, NA, and HA genes. Therefore, each 
gene sequence of the wt A/Ann Arbor/6/60 virus was 
also compared with influenza A (H3N2) gene se- 
quences available in the Gen Bank data base at the 
time of analysis. 
NS1 and NS2 sequences 
The smallest RNA segment of influenza virus is 890 
nucleotides long and codes for the NS1 and NS2 poly- 
peptides that are found only in infected cells (Inglis et 
a/., 1979; Lamb and Choppin, 1979; Lamb etaL, 1980). 
The functions of NS1 and NS2 are unknown. The com- 
plete nucleotide sequences for the NS genes of the A/ 
Ann Arbor/6/60 mutant and wt viruses are shown in 
Fig. 1. Two nucleotide differences were detected be- 
tween the ca mutant and wt viruses with a coding 
change at nucleotide 483 in the portion ofthe gene that 
encodes NS1 and a noncoding change at nucleotide 
813 in the portion of the gene that encodes NS2. The 
former nucleotide change encodes an alanine to three- 
nine substitution in the mutant NSl protein at amino 
acid 153. Comparison of the sequence we obtained for 
the A/Ann Arbor/6/60 wt NS gene with the sequence 
for this gene published previously (Buonagurio et al., 
1986) revealed complete agreement, with only one ad- 
ditional change compared to the sequence of the A/ 
WSN/33 virus in a region not sequenced previously (T 
at nucleotide 35 in both ca and wt A/Ann Arbor/6/60 
viruses). Volunteer studies with reassortant candidate 
vaccine strains having an RNA 8 from the H1N1 or 
H3N2 wild-type parent indicated that this gene is not 
required for attenuation (La Montagne et al., 1983). 
Studies with single gene reassortants are also consis- 
tent with the conclusion that RNA 8 does not contrib- 
ute significantly to attenuation (Snyder et al., 1987). 
M1 and M2 sequence 
RNA segment 7 is 1027 nucleotides long and codes 
forat least two proteins, M1 and M2 (Allen etaL, 1980; 
Winter and Fields, 1980; Lamb et al., 1981). The M1 
protein is a viral structural protein of 252 amino acids. 
The M2 protein is 97 amino acids in length and, al- 
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10 30 50 70 90 110 
mt • 
wt RG~RRRRGCRGGGTGRCRRRGRCRTRRTGGRTCCTRRCRCTGTGTCRRQ~T~CRGGT~RTTGC~CCTTTGG~RTGT~GCRRRCR~TT~RGR~CRRGRRCTR~GTGRTGCCCCRT 
ut  N-terminus ~ 1  and NS2 M O P N T V S S F Q V O C F L H H V R K O U R O Q E L G O R P F(32) 
mt 
130 150 170 190 210 290 
mt 
wt TccTTGRTcGGC~CGCCG~Tc~G~GTCCCT~GGGG~G~GGc~G~cTcTc~TcT~R~TcGRRR~R~C~RCCc~T~TT~GRR~Gc~G~T~GTGG~G~G6~TTCTGR~GG~G 
wfi L O R L R R 0 0 K S L R G R 0 S T L 6 L N I E T R T R V S K O I V E R I L K E E(72) 
mt 
250 270 290 316 330 350 
~t 
wk RRTCC~RT~R0~CRCTTRRRRT~RCCRT66CCTCC~C~CCT~C~RTRCCTR~TGRCRT~TRTT~R~RRRT0TCRRB0BR~0TTCRT0CTRRTGCCCRR~R~RRR0T~ 
S D E R L K M T M R S R P R S R Y L T O N T I E E M S R O H F M L M P K 6 K U R(112) 
m~ 
370 390 410 430 450 476 
mt 
ut CR~C~T~TTT6TRTCRGRRT~RCCR~CRRTCRT~RTRR~RRCRTCRTRTT~RRR~C0RR~T~R~T~T~RTTTTT~R~C~CTR0R~RCCCTRRTR~RCTRR~CTTTCRCC6 
ut G P L C I R H O Q R I M O K N I I L K R N F S U I F O R L E T L I L L R R F T E(152) 
mt 
490 510 590 550 570 590 
mt R 
u t  RRGCG~R~CRRTTGTT~CGRRRTTTCR~CRTT~CCTTCTCTTc~R~G~RTRCTRRT~RGGRTGTCRRRRRT~CRRTT0~TC~T~RTCGGR~GR~TT~RRT0GRRTGRTRRCRCR~ 
wt R 6 R I V G E I S P L P S L P G H T N E O U K N R I 6 V L I 0 0 L E N N O N T V(192) 
mk T 
ut D I L M R M S K N Q L G S S S E D L N G M I T Q (34) 
mt 
610 6£0 650 070 690 710 
mt 
ut TTC~R~TCTCTRRRRCT~TRCR~RGRTTC~CTT~R~RR~CR~T~RT~R~RRT~R~RCCTCCR~TCRCTCCR~RTR~RRR~66RRRRT~R~RRCRRTTR~0TCRRRR0TTC~RR 
ut R V 5 K T L 0 R F R H ~ S S O E N 6 R P P L T P K (217) C-terminus NS1 
mt 
ut F E S L K L Y R D S L G E R V M R M G D L H S L Q N R N 0 K N ~ E Q L 0 Q K F E (74) 
mt 
730 750 770 790 810 830 
mt 6 
ut ~RRRTRR~RT~T~RTT~RR~RR~TGR~RCRCRRR~RRGRTRRC~GR~RRTR~TTTT~R~CRRRTRR~RTTTRT~RR~CCTTRCR~CTR~TRTTT~RR~T~RRCRR6R~RTRR~R 
wt E I R H L I E E U R H K L K I T E N S F E Q I T F M Q R L Q L L F E V E Q E I R (114) 
mt 
B56 870 B90 
mt 
ut  RCTTTCTCGTTTCRGCTTRTTTRRTGRTRRRRR~RCCC~G~TCTRCT 
uk T F S F g L I (12t )  C-terminus NS2 
mk 
F~G. 1. Nucleot ide and protein sequences of RNA segment  8 of the A / A n n / A r b o d 6 / 6 0  wt  and ca mutant  viruses. Complete sequences are 
shown for the w t  viruses. Nucleot ide changes detected in the mutant  RNA are shown above the wt  sequence,  whi le predicted amino acid 
changes in the mutant  are shown below the w t  sequence.  Splice junct ions for NS2 are indicated by arrowheads. 
though its function is unknown, this protein is known 
to be inserted into plasma membranes of infected cells 
(Zebedee et al., 1985). Complete nucteotide sequence 
data for RNA 7 of A/Ann Arbor/6/60 ca mutant and wt 
viruses (Fig. 2) demonstrate that there was a single 
difference (G to T) at nucleotide 969. This nucleotide 
substitution encodes a change from alanine in the wt 
to serine in the mutant at amino acid 86 of the M2 pro- 
tein. Comparison of the Ann Arbor/6/60 M2 sequences 
with those of other strains indicated that the M2 genes 
of the three other wt human strains sequenced to date 
have alanine at amino acid 86 of M2. This amino acid 
has been identified as one that varies between human 
and avian influenza strains (Buchler-White etaL,  1986). 
Amino acid 86 is a part of the trypsin-sensitive carboxy- 
terminal tail (Zebedee et  al., 1985). One ca candidate 
vaccine strain, CR 31 Clone 3, that received the seg- 
ment 7 from its wt parent in addition to the HA and NA 
genes (Cox et  al., 1979) was attenuated in seronega- 
tive adult volunteers (La Montagne et  aL, 1983), but 
was less restricted in its replication in humans than a 
similar reassortant with segment 7 from the ca parent 
(Murphy et al., 1981). In addition, a reassortant with 
only the genes encoding the PA, M1, and M2 proteins 
from the ca A/Ann Arbor/6/60 virus was as attenuated 
in human volunteers as another reassortant virus hav- 
ing all but the HA and NA genes from the ca donorvirus 
(Snyder et  aL, 1985). Further studies with single seg- 
ment reassortant viruses also suggest that either the 
M1 or M2 proteins may play a role in attenuation (Sny- 
der et  al., 1987). Sequence data presented here sug- 
gest that the M2 protein may be responsible for the 
observed biological findings. 
NP sequence 
The nucleoprotein gene [RNA segment 6 of the A/ 
Ann Arbor/6/60 viruses under electrophoretic condi- 
tions used to separate RNA (Cox et al., 1985)] is 1565 
nucleotides in length and encodes a basic structural 
protein of 498 amino acid residues that specifically in- 
teracts with RNA molecules to form ribonucleoprotein 
complexes (Winter and Fields, 1981; Huddelston and 
Brownlee, 1982) and has sequences that direct its mi- 
gration into the nuclei of infected cells (Davey et  aL, 
1985). Three nucleotide changes were detected in the 
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i0 30 50 70 96 I i0  
mt 
wt RGCRRRRGcRGGTRGRTRTTGRRR~RTGRGTcTT~TRRCCGRGGTcGRRR~GTRcGTTcTCTcTRTCRTCCC~TCR~GC~C~CTcRRR~CCGRGRT~G~R~RGRGRCTTGRRGRTGT~TT 
wt N-terminus M1 and M2 M S L L T E V E T Y V L S I I P S G P L K R E I R 0 R L E 0 V F (~ )  
mE 
130 156 170 190 210 230 
mt 
wt TG~TGGGRRRRRCR~CGRTCTT~RGG~TCTCRTGGRRTGGCTRRRGRCRRGRCCRRTCCTGT~RCCTCTGRCTRRGGGGRTTTTGGGRTTTGTRTT~RCGCT~RCCGTGC~RGTGRGC~ 
wt R G K N T 0 L E R L M E N L K T R P I L S P L T K G I L G F V F T L T V P S E R(72) 
mt 
250 270 290 310 330 350 
mt 
wt R~GRCTGCRGCGTRGRCGCTTTGTCCRRRRTGCC~TCRRTGGGRRTGG~GRTCCRRRTRR~RT~RCRGRGCRGTTRRR~TGTRTRGRRRGCTTRRGRGGGRGRTRRCRTTCCRTGGGG~ 
wL G L O R R ~ F V 0 N R L N G N G 0 P N N M 0 ~ R V K L Y ~ K L K R E I T F H G R(112) 
mE 
370 396 416 430 450 470 
mE 
wL cRRRGRRRTRGCGCTCRGTTRTTCTGCTGGT~R~TTGCCRGTTGTRTGGGC~TCRTRTR~RRCR~GRTGGGGGCTGTGRCCRCT~RRGTGGTCTTRG~CCTGGTRTGTG~RR~TGTGR 
wt K E I R L S Y S R G R L R S C M G L I Y N ~ M G R V T T E V V L g L V C R T C E(152) 
mt 
490 510 530 550 570 590 
mt 
wt RCRGRTT~CTGRCTCC~RGCRTR~gTCT~RTRGGCRRRTGGTGRCRRCRRCCRRTC~R~TRRTRRGR~RT~R~RRCRGRRTGGTT~TGGC~RGCR~TRCR~CTRRG~TRTGGRG~RRRT 
wt O I R 0 S O H ~ S H R 0 M V T T T N P L I ~ H E N ~ M V L R S T T R K R M E 0 H(192) 
mt 
616 630 650 670 690 710 
mt 
wt GGCTGGRTCGRGTGRG~RRGCR~CR~R~G~CRTGGRGGTTGCTRGTCRGGCCRGGCRRRTgGT~CRGG~RRTGRGRGTTRTTGGGRCT~RTCCTRGCTC~RGTGCTGGTCTRRRRRRTGR 
wt R G S S E 0 R R E R M E V R S 0 R ~ 0 M V O A M ~ V I G T H P S S S R G L K N 0(232) 
790 750 770 "790 810 8"~0 
mt • 
wE TCTTCTTGRRRRTTTGCR~GCCTRTCRGRRR~GRRTGGGGGTGCRGRTGCRRcGRTTCRRGTP~RCCCTCTTGTTGTTGCCGCGRGTRTCRTTGGGRTCTTG~RCTTGRTRTTGTGGRTT~ 
wt L L E N L O R Y O K I~ M G V O M O R F K (252) C-fierminu= MI 
mt 
wt P I R N E N G C I~ C N O S S O P L V V R R S I I r. I L H L I L N I L(43) 
mt 
850 870 890 910 930 950 
mt 
wt TTGRTCRTCTTTTTTT~RRRTP~RTTTRT~GcTTCTTTRRR~RC~̀GTcT~RRRRGRGGGccTTCTRcGGRR~P~RGTRCCR~R~TCTRT~RG~̀RR~̀RRTRTC~̀RRRGP̀RR~RGcRP~R~T r- 
wL 0 H L F F K C I Y R F F K H G L K I~ G P S T E G V P E S M R E E Y I~ K E 0 0 S R(83) 
mt 
976 990 1010 
mt T 
wt CTGTP-GRTGCTGRCGRTRr-TCRTTTTr-TCRGCRTRGRGCTGGRGTRRRRRRCTRCCTTP-TTTCTRCT 
wL V 0 R 0 0 S H F V S I E L E (97) C-terminus N2 
mE S 
FIG. 2. Nucleotide and protein sequences of RNA segment 7 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are 
shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid 
changes in the mutant are shown below the wt sequence. Splice junctions for M2 are indicated by arrowheads. 
mutant NP gene sequence (Fig. 3) A change at nucleo- 
tide 113 encodes an amino acid substitution from thre- 
onine in the wt to a sparagine in the ca mutant at amino 
acid 23, and a change at nucleotide 146 encodes an 
amino acid substitution from aspartic acid in the wt to 
glycine in the ca mutant at amino acid 34. The change 
at nucleotide 113 is not present in NP genes of other 
influenza viruses sequenced, while the change at nu- 
cleotide 146 is also present in the highly passaged lab- 
oratory strain, A/PR/8/34. The other change in the NP 
gene of the mutant is the insertion of a single A nucleo- 
tide in an A-rich region (1545-1550) that is near the 
putative polyadenylation signal (Robertson et aL, 
1981). This insertion may not be important because 
other influenza virion RNA segments have poly(U) 
tracts of varying lengths in corresponding positions. Al- 
though a ca NP gene was present in all the candidate 
vaccine strains we examined (Cox et al., 1986), no 
compelling genetic evidence exists to show that the 
NP genes of the ca mutant and wt A/Ann Arbor/6/60 
viruses are associated with different phenotypic prop- 
erties (Snyder et al., 1987); therefore, the significance 
of the mutations in RNA 6 is unknown. 
PA sequences 
RNA segment 3 is 2233 nucleotides in length and 
encodes an acidic polymerase protein (PA) 716 amino 
acids in length (Fields and Winter, 1982; Bishop et  al., 
1982b; Robertson et  al., 1984). The complete nucleo- 
tide sequences for the PA genes of A/Ann Arbor/6/60 
mutant and wt viruses are presented in Fig. 4. Four nu- 
cleotide changes were detected in the mutant gene, 
with two of these changes located in the same codon. 
A change at nucleotide 20 (U to C) is in the noncoding 
region. Comparison of the A/Ann Arbor/6/60 se- 
quences with published sequences revealed that A/ 
PR/8/34 and the Rostock strain of fowl plague virus 
have C at nucleotide 20 (Fields and Winter, 1982; Rob- 
ertson et aL, 1984), while A/NT/60/68, like the A/Ann 
MUTATIONS IN INFLUENZA A/Ann Arbor/6/60 ca VIRUS 559 
10 30 50 70 90 110 
mt R 
RGC~R~GCRGGGTRGRT~TC~CTCRCTGRGTGRCRTC~TCRTGGCGTCCCRRGG~C~RRRCGGTCTTRTGR~RG~TGGRR~TGRTGGGGR~CGCCRGRRTGCRRCTGRRRTC 
ut M R 5 0 G T K R 5 Y E 0 M E T 0 G E R 0 N R T E I(25) 
mt N 
130 150 170 190 210 230 
mt B 
RGRGC~TCCG~GGG~RGRTGRTTG~TGGRR~GG~GRTT~TRCRTCC~TGTGC~GRRCTTR~T~TG~T].~TG~GGGGCGG~TGRTCC~G~RC~GCTTR~RTRGA~G~ 
~ R R G V G K M I D G I G R F Y I 0 M C T E L K L 5 D Y E G R L I 0 H S L T I E R(65) 
mt G 
250 270 290 310 330 350 
mt 
RTGGTGCTCTCTgCTTTTGRCGR~RgG~GR~TRRRTRTCTGGRRG~RC~TCC~R~CGCGGGGRR~RT~TRR~RR~RCTgGRGG~C~T~T~CRRGR~R~TRGRTG~RRR~TGG~TG 
~ M V L S R F 0 E R R H K Y L E E H P S R G K 0 P K K T G G P I Y K R V 0 G K H M(I05) 
mt 
370 390 410 430 450 470 
mt 
w~ RG~RCT~GTCCTTTRTGRC~GRR~RR~TRR~GC~RTCTGGC~CCRRGCTR~TRRTGGT~RTGRTGC~RCRGCT~GTCTG~TC~C~T~RT~RTCT~GCRTTCCRRTTT~RRTG~T 
~ R E L V L Y D K E E I R R I W R Q R N H G 0 0 R T R G L T H M M I W H 5 N L N 0(145) 
mt 
490 510 530 550 570 590 
mt 
wE ~C~R~TR~CRG~GG~CRAG~GCTCTTG~CGCRCCGG~TGG~T~CCRGGATGTGCTCTTTG~TGCRGGGTTCG~CT~TCC~T~G~GGTCTGGRG~CG~GGCGCTGC~GTCR~RGGR 
wE T T Y 0 R T R A L V R T G M 0 P R M C S L M Q G S T L P R R S G A R G R R V K G(IB5) 
mE 
610 630 650 670 690 710 
mE 
wE GTTGGGR•RRTGGT•TGG•GTTGRTRRGGRTGRTCRRRCGTGGGRTCRRTGRTCGGRRCTTCTGGRG•GGTGRGRRTG•GCGG•RRR•RRGGRRTGCTTRTGRGRGRRTGTGCRRCRTT 
uE U G T M V M E L I R M I K R G I H 0 R N F N R G E H G R K T R H R Y E R M C N I(225) 
mE 
730 ~0 770 790 810 830 
mE 
wE CTCRRRGGRRRRTTTCRR~CRGCTGCR~RRRGRGCRRTGRTGGRTCRRGTGRGRGRRRGCCGGR~C~GGRR~TGCTGRGRT~GRRGRTCTCRTCTTTCTGGCRCGGT~TG~RCT~RTR 
wE L K G K F 0 T R R 0 R R M M 0 0 V R E 5 R H P G H A E I E 0 L I F L R R 5 R L I(265) 
mE 
850 870 890 910 930 950 
mE 
TTGRGRGGG~GTTGCTCRCRRRTCTT~TCTG~CTG~CTGTGTGTRTGGRCCTGCCGT~GCC~GT~GCTRCGRCTTCGRRR~RGRGGGRTRCTCTTTRGTRGGGRTRGRC~CTTTCRRR 
wEL R ~ 5 U A H K S C L P R C U Y G P R V R 5 G Y 0 F E K E G Y S L V G I D p F K(305) 
mE 
970 990 1010 1030 1050 1070 
mE 
~TG~TTCRRRRCRGCCRRGTRTRCRGCCTRRTCR~RCCGRRTGRGRRTCCRGC~:~CRCRRGRGTCRGCTGGTGTGGRTGGCRTGC~RTTCTGCTGCRTTTGRRGRTCTRRGRGTRTCRRGC 
wE L L Q N S Q V Y S L I R P N E H P R H K S 0 L U W M R C N S R R F E 0 L R V 5 5(345) 
mE 
I090 1110 1130 1150 1170 1190 
mE 
TTC~T~NGRGGGRC~RRGT~NTC~C~NGGGGGRNN~TTTCCRCTNG~GRGT~RRTTGCTTCRRRTG~ARRCRTGGRTRCTRTGGGNTCNAGT~CTCTTGN~TGNg~AGCRGGTN~ 
~ F I R G T K V I P R G K L 5 T R G V 0 1 R  5 H E H M 0 T M G S 5 T L E L R S R y(385) 
mE 
1210 1230 1250 1270 1290 1310 
mt 
TGGGC~TA~CC~GR~GTg~AGGAR~CACTA~T~AC~RGGGCCTCTG~GTCARRTC~GTGT~C~R~CT~C~TTTTCT~TGCRA~CCTC~CATTTG~AAC~AAC~AT~ 
wE N A I R T R 5 ~ G N T N Q 0 R R 5 A G 0 I 5 V 0 P T F S U ~ R H L p F 0 K p T i(425) 
mE 
1330 1350 1370 1390 1410 1430 
mE 
~k ~TGGC~GCRTT~ACTGGGRRT~RGGGRRGRR~RTC~RCRTG~GCAGARRTCRTRRG~RTGRTGGRAGGTG~AR~C~RRGRRgTGT~TT~CRGGGGcGGGG~GT~TTCGRG 
wE M R R F T G H R E G R T 5 0 M R R E I I ~ M M E G R K p E E U S F 0 G R G V F E(465) 
mE 
1450 1470 1490 1510 1~0 1550 
mE R 
CT~T~G~RCGRRARGG~RRCGRRC~GRTCGTGC~T~TTTTGR~RTGRGT~RTGRRGGRTC~RTTTCTTCGGRGR~RRTGCRG~GGRGTR~GRCRRTTRR~GRRRRR~T~TTGTT • 




Fie. 3. Nucleotide and protein sequences of RNA segment 6 (NP) of the A/Ann/Arboff6/60 wt and ca mutant viruses. Complete sequences 
are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid 
changes in the mutant are shown below the wt sequence. The single nucleotide inse~ion is indicated by a 0 in the wt sequence at position 
1550. 
Arbor/6/60 wt, has U (Bishop et al., 1982b). Thus it 
seems unlikely that this U to C change is important in 
attenuation. It is possible, however, that this change 
could alter base pairing of the ends of the RNA seg- 
ment or polymerase recognition (Skehel and Hay, 
1978; Robertson, 1979; Stoeckle etaL, 1987). A single 
base change in the noncoding region of the poliovirus 
3 genome has been shown to affect attenuation (Evans 
et al., 1985). A change from A to G at nucleotide 1861 
encodes a lysine to glutamic acid substitution at amino 
acid 613. While this is a change from a basic to an 
acidic residue, it is not likely by itself to be involved in 
attenuation because comparison with other se- 
quences revealed that A/PR/8/34, A/FPV/Rostock/34, 
and A/NT/60/68, like the A/Ann Arbor/6/60 mutant vi- 
rus, all have glutamic acid at residue 613. The two 
other changes are in the same codon (-i-i-A to CCA at 
nucleotides 2167 and 2168), resulting in a predicted 
amino acid substitution at residue 715 (the penultimate 
amino acid in the PA protein) from leucine in the wt to 
560 COX ET AL. 
I0 30 50 70 90 II0 
m~ C 
u~ ~C~CRG~T~CT~RTTC~R~T~G~RGATTTT~T~C~RC~T~CTTCA~TCC~T~RTTGTC~R~CTTGCTG~RRR~CR~T~R~T~T~GAGR~T~TG~TC~R~RCR 
u~ M E O F V R O C F N P M I V E L R E K A M K E Y G E O L K I E T ( 3 2 )  
mt 
130 150 170 190 210 230 
m~ 
u~ R~CRRRTTT~CR~CR~TRTGCRCTCRCTT~GRRGTRT~CTTCRTGTRTTCR~RTTTTCRTTTCRTCRRTGR~CRR~GC~R~TCRRTRRTR~TRGRGCTT~RT~RTCCRR~T~CRCTTTT~ 
u E H K F R R I C T H L E V C F M Y S O F H F I N E 6 G E S I I V E L O O P N R L L ( 7 2 )  
mt 
250 270 290 310 330 350 
mt 
wt ~R~CRC~RTTT~R~RT~RTRG~G~TC~CRC~T~CCT~6RCR6T~6TR~RC~T~TTT~C~CRCT~CR66~GCT6~RCC~RR~TTTCT~CCRG~TTT~T~TG~TT~C 
w t K H R F E I I E G R D R T M R N T V V N S I C N T T G R E K P K F L P O L Y O Y ( I I 2 )  
mt 
370 390 410 430 450 470 
mt 
ut RR~RT~RTTCRTC~R6RTT~R~T~RCRR~RG6~R~TCCRC~TRTRCT~TCTT~RR~CCR~TR~RTTR~TCT~R~R~RC~CRCRT~CRCRTT~CTCRTTC~CT~ 
w £ K E N R F I E I G V T R R E V H I Y Y L E K R N K I K S E K T H I H I F S F T 6 ( 1 5 2 )  
mt 
490 510 530 550 570 590 
mt 
ut ~GRR~TG~CCRCR~CC~CT~C~CTCTC~RTGR6~C~CTR~RTC~R~CCR~RCTRTTCRCC~TRR~RCRR~R~RT~CT~GCR~R~CTCT~RTTCCTTTC~T 
w t E E M R T K R O Y T L O E E S R R R I K T R L F T I R O E M R S R G L N D S F H ( 1 9 2 )  
mt 
610 630 650 670 690 710 
mt 
ut CR~TCC~RR~R~GC~RR~RRRCRRTT~RR~RRR~RTTT~RRRTCRCR~R~RRT~C~R~TC~CC~RCCRRR~TCTCCC~CC6RRCTTCTCCT~TT~R~RRTTTTR~R~CCTRT 
w ~ O S E R G E E T I E E R F E I T G T M R R L R O 6 5 L P P N F S C L E N F R A Y ( 2 3 2 )  
mt 
730 750 770 790 BlO 830 
mt 
ut 6T~RT~6RTTC~RRCC~RRC~CT~RTTGR~CRR6CTTTCT~RRRT~T~R~R6RR~TRRRT~CTRRR~TT~RRCCTTTTCT~8~R~R~CRC~R~R~RTTRGRCTTc~GRT 
u t V O G F E P N G Y I E G K L S O M S K E V N R K I E P F L K T T P R P I R L P O ( 2 7 2 )  
m~ 
850 870 890 910 930 950 
mt K 
ut ~CCTCCTT~TT~TCR~TCCRRRTTCCT~T~RT0~T~CTTTRRRRTT~6CR~R~GRCCCRRGTCRC~RR~RGRG~GRRTRCCRCTRTRT~RT~C~RTCRR~T~TRT~R~R 
wt G P P C 5 6 R 5 K F L L M 0 R L K L 5 I E 0 P 5 H E 6 E 6 I P L Y 0 R I K 0 M R(312) 
m~ 
970 990 I010 1030 1050 1070 
m~ 
u~ RCRTTCTTT~RT~RRR~RRCC~T~T~TT~TTRR~CCR~C~RRRR~RT~T~C~TTRT~CT~RT~RR~CRR~TRCT~CR~RRCT~CR~RCRTT~6RRT~R~R~ 
u~ T F F 0 N K E P Y V V K P H E K G I N P N Y L L" 5 W K 0 V L R E L 6 0 1 E  N E E(382) 
mk 
I090 1110 1130 1150 1170 llgO 
mt 
w~ RR~RTTCCRR6RRCCRR~RRCRT~RR~RRRRCGR~T~R~CTRRR~T~CRCTT~TGRGRRCRT~RCCR6R~RR~TR~RCTTT~RC~RCTGTR6R~RT~TRRG~G~TTT6RR~CRR 
ut K I P R T K N M K K T 5 6 L K H R L G E N M R P E K V D F 0 0 C R 0 V 5 0 L K 6(392) 
mt 
1210 1230 1250 1270 1290 1310 
mt 
wt TRT~RTR6T~RT~RRCCT6~TTRR~RCTTT~RR~cT~TC~R~RRT~R~TTCRRCRR~CRT~C~R~CT~RC~RTTCRRTCT~T~6~Tc~RT~R~RR6RT~T6 
u t Y D S O E P E L R S L S S W I O N E F N K R C E L T O S I N I E L O E I G E O V ( 4 3 2 )  
mt 
1330 1350 1370 1390 1410 1430 
mt 
w~ 6CTCCRRTT~RR~RTT~C~G~RT~6~RRTTR~TTC~R~RGR6~TGTCTCRTT~CR6~CC~6~RTRT~T~RT~T~RTT~TRcTGCCTT~TTR~T~C~ 
w ~ R P I E H I A S M R R N Y F T R E V S H C R R T E Y I M K G V Y I N T R L L N A ( 4 7 2 )  
mt 
1450 1470 1490 1510 1530 1550 
mt 
wt TCCT~T~CR~C~RT~R~RTTT~CRRCTRRTTCCCRT~RTRR~CR~T~TR~RCTRRR~R66C~RRR~RCCRRTTTRTRT~TTTCRTCRT~RRR6~RR~RT~TCR~TTR~G 
ufi S C R R M 0 0 F 0 L I P M I 5 K C R T K E 6 R R K T N L Y 6 F I I K 6 R S H L R(512) 
mfi 
1570 1590 1610 1630 1650 1670 
mt 
w~ RRT••CRCC6RC6TGGT•RRCTTT6T•R•CRT••R•TTTTCTCTCRCT••CC••R•RCTT•••CCRCRCRRRT•••R•R•6TRCT•T•TTCTT•R••T•••R••TRT•CTRCTRRGR••T 
wt N 0 T D V V N F V 5 M E F S L T D P R L E P H K W E K Y C V L E I 6 0 M L L R 5(552) 
mt 
1690 1710 1730 1750 1770 1790 
mk 
uk 6CCRTR~CCR~6T~TC~R~CCCRT~TTCTTGTRT6T~R6~R~RRRT~6RRCRTCRRR6RTTRRRRT~RRRT0~RRT~R~RT~R~TT~TCCTT~TCRCTCCRRCRR~TC 
u ~ R I G 6 V S R P M F L Y V S T N G T S K I K M K N G M E M R R C L L 6 5 L 0 6 1 ( 5 9 2 )  
mt 
1810 1830 1850 1870 1890 1910 
mfi G 
w~ ~R~R~TRTGRTT~RR~R~TCCTCTGTCRR~R~R~RCRT~RR~R6TTTTT~R~RT~RTCR~RRRCRT0~CCCRTT~R~R~TCCC~RRR~R~T~RR~RR~GTTC~ 
w t E S M I E A E S S V K E K O M T K E F F K N K S E T N P I G E S P K G V E E G 5 ( 6 3 2 )  
mt E 
1930 1950 1970 1990 2010 2030 
mt 
ut RTT••6RR6•T•T•CRG•••TTTRTTRGCCRR•T•••TRTTCRRTR••CT•TRT•CRTCTCCRCRRTTR•RR••RTTTT•R•CT6RRT•RR•RRRR•T•CTT•TT•TC•TTC•••CTCTT 
wL I 9 K V 0 R T L L R K S V F N 5 L Y R S P 0 L E 6 F 6 R E S R K L L L V V 0 R L(672) 
mL 
2050 2070 2090 2110 2130 2150 
mk 
wk ~6~R~RRTCTT~R~T6~R~TTT6RT~TT~666GCT~TRT6R~C~RTT6R~T~CCT~RTT~T6~TC~T66~TTTT6CTTRRT~C~TCTT~TT~RR~TC~TTC~T~RC~ 
w k R O N L E P G T F O L G G L Y E A I E E C L I N O P N V L L N R S N F N S F L T ( 7 1 2 )  
mt 
2170 2190 2210 2230 
mk CC 
wk CRTGCRTTRRGRTR6TTGTG6CRRTGCTRCTRTTTGCTATCCRTRCT6TCCRRRRRRGTRCCTTGTTTCTRCT 
uk H A L R (716)  
mt P 
FiG. 4. Nucleotide and protein sequences of RNA segment 3 of the A/Ann/Arbod6/6O wt and ca mutant viruses. Complete sequences are 
shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid 
changes in the mutant are shown below the wt sequence. 
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proline in the ca mutant. Although two nucleotide 
changes were found in the same codon, only a single 
nucleotide change from CCA to CTA is required for re- 
version back to leucine by the mutant. The other three 
influenza viruses sequenced to date have leucine at 
residue 715 of their PA proteins. The PA gene has been 
demonstrated to be involved in the cold-adaptation and 
attenuation properties of the mutant (Odagiri et al., 
1986; SnyderetaL, 1985, 1987), so this leucine to pro- 
line change may be relevant to virus phenotype. 
PB1 sequence 
RNA segment 2 is 2341 nucleotides in length and 
encodes a basic polymerase protein (PB1) 757 amino 
acids in length (Winter and Fields, 1982; Bishop et aL, 
1982a; Sivasubramanian and Nayak, 1982). Seven nu- 
cleotide differences were detected between the A/Ann 
Arbor/6/60 mutant and wt PB1 gene sequences (Fig. 
5). Changes at nucleotides 123 and 486 were noncod- 
ing changes. Four coding changes were found at nu- 
cleotides 1195, 1395, 1766, and 2005 followed by a 
noncoding change at nucleotide 2019. The four coding 
changes result in amino acid substitutions of lysine to 
glutamic acid at amino acid 391, glutamic acid to 
aspartic acid at amino acid 457, glutamic acid to gly- 
cine at amino acid 581, and alanine to threonine at 
amino acid 661. None of these four changes exists in 
the three other wild-type PB1 genes sequenced to 
date, so any or all of them may be involved in the biolog- 
ical properties of the virus. Because RNA 2 of the mu- 
tant was absent in several ca reassortant vaccines that 
were fully attenuated (La Montagne eta/. ,  1983), its 
role in attenuation has been questioned. Earlier genetic 
evidence (Cox eta/., 1981) and more recent evidence 
using single gene reassortants in several animal 
models, however, suggest that mutations in RNA 2 
may contribute to the temperature-sensitive and atten- 
uation phenotypes of the ca A/Ann Arbor/6/60 virus 
(Snyder et al., 1987). 
PB2 sequence 
RNA segment 1 is 2341 nucleotides in length and 
encodes a basic polymerase polypeptide (PB2) of 759 
amino acids (Fields and Winter, 1982; Kaptein and 
Nayak, 1982; Jones etaL, 1983; Roditi and Robertson, 
1984). The complete nucleotide sequences of the A/ 
Ann Arbor/6/60 mutant and wt PB2 genes are shown 
in Fig. 6. Seven nucleotide differences were detected 
between mutant and wild-type sequences, at nucleo- 
tides 141, 426, 821, 1182, 1212, 1353, and 1923. 
Only the A to G change at nucleotide 821 encodes an 
amino acid change, from asparagine in the wt to serine 
in the mutant at amino acid 265. Examination of the 
other PB2 sequences available for other wt influenza A 
viruses revealed that asparagine is present at amino 
acid 265 in each case. However, a lower passage (E3) 
A/Ann Arbor/6/60 wild-type virus sequenced in another 
laboratory, like the ca mutant, had serine at amino acid 
265 (Herlocher, personal communication). The other 
six changes, Ato G, U to C, Ato U, C to U, U to G, and 
Ato G at nucleotides 141,426, 1182, 1212, 1353, and 
1923, respectively, are all silent mutations within the 
coding region. All A/Ann Arbor/6/60 ca reassortant 
vaccines tested in clinical trials thus far (except single 
segment reassortants) derive their PB2 gene from the 
ca parent (Cox et al., 1986; Maassab, personal com- 
munication), and early genetic data indicated that RNA 
1 may be involved in the temperature sensitivity of the 
mutant (Spring et aL, 1977). More recent results using 
single segment reassortant viruses also indicate that 
RNA 1 contributes to the temperature-sensitive pheno- 
type of the ca mutant (Snyder et aL, 1987). 
DISCUSSION 
Here we describe the complete nucleotide se- 
quences for the genes encoding the NS1, NS2, M1, 
M2, NP, PA, PB1, and PB2 proteins of the cold- 
adapted and wild-type A/Ann Arbor/6/60 (H2N2) vi- 
ruses. Few sequences are published for genes of 
H2N2 viruses. Such data are of evolutionary and epide- 
miologic significance because H2N2 viruses are pro- 
posed to be the immediate ancestors of the H3N2 sub- 
type (Scholtissek et al., 1978; Nakajima et aL, 1982). 
Comparisons between the wt A/Ann Arbor/6/60 gene 
sequences and those published previously for the 
H3N2 viruses A/NT/60/68 or A/Udorn/72 indicate that 
yearly rates of mutation of 0.36, 0.24, 0.28, 0.40, 0.68, 
and 0.49% occurred for the NS, M, NP, PA, PB1, and 
PB2 gene segments, respectively. These observations 
are consistent with the derivation of these genes in the 
H3N2 viruses from previously circulating H2N2 vi- 
ruses. 
We have identified 24 nucleotide differences be- 
tween the A/Ann Arbor/6/60 ca mutant donor strain 
and its wt parent (Table 1). These 24 nucleotide 
changes constitute 0.2% of the total number of nucleo- 
tides sequenced. Our previous estimate (based on T1 
oligonucleotide mapping studies) that as many as 40- 
60 nucleotide changes might have occurred in the total 
genome of the ca mutant (Cox et al., 1986) was inaccu- 
rate. Comparison of deduced amino acid sequences 
for the parental and mutant viruses revealed 11 amino 
acid differences or 0.26% of the total number of amino 
acids (Table 1). Sequences for four other pairs of wt 
and attenuated viruses have been compared, and the 
1o 90 50 70 90 110 
~t 
ut R•••••R•cR••c•••Cc•TTT•R•T66RT•T••RTcc6••cTT•cTTTT•TT•••R•TTCCR6C6c•R••T6CC•TRR•T•cTRCRTTCCCTTRTRCT66R••T••TCCRT••R••c•T 
~t M O V N P T L L F L K V P R O N R I S T T F P Y T G D P P Y S H ( 9 2 )  
mL 
190 150 170 190 210 290 
mE G 
=E ~RC~RRcR~6RTR~RCCRT~R~R~R~TCRR~RRCR~RTCRRTR~CR~RRRR~RR~T~R~RRR~R~6RRRCT~R~CR~cRR~TTRRC~RRTT6RT~R~cR 
~ = f i G T G T G Y T M O T V N R T H Q Y S E K G K W T T N T E T G R H O L H P I D G P ( 7 2 )  
mE 
250 270 290 910 990 950 
mE 
wE ~TRC~T~R~GR~R~T~R~RR~T~TRT~C~RRR~GR~TG~GTC~T~RR~RT~TTT~TT~RRGRRT~RC~RGG~RT~TTT~R~TC~T~T~TT~RRR~RTGG~R 
u E L P E O N E P S G Y R O T O C V L E R M R F L E E S H P G I F E N S C L E T M E ( l l 2 )  
mE 
970 990 410 490 450 470 
mE 
uL ~TTRTT~RRCRRRCRR~R~TG~RcRRRcTGRC~cRRG~TC~TCR6R~cTRT~RTT~RcRTT~RR~R~RRRT~R~c~T~RR~TGc~TRG~cRR~RcTRTR~R~TCTTcR~RT~ 
= E U I O O T R U D K L T O G R O T Y O N T L N R H Q P R R T R L R N T I E U F R S ( 1 5 2 )  
mE 
490 510 590 550 570 590 
mE T 
=E RRT~CCT~RCR~TRRT~RRTC~RR~TRRTR~RTTT~T~RR~RT~T~RTR~RRT~RRT~RTRRR~R~RT~GRRRTcR~RRcR~R~TTC~RR~RRRRR~RR~R~TRR~R 
w L N g L T R N E S 6 R L I O F L K O V I E S M O K E E M E I T T H F O R K R R U R ( 1 9 2 )  
mE 
610 690 650 670 690 710 
mE 
wE ~R~RR~RT~R~RR~RRRT~GTCR~R~RR~RR~RRTRG~RRR~R~RR~C~R~RTT~RR~R~8RR~TRT~TRRTRRGRGCR~T~R~TTGRR~RCRRTGRCT~RR~T~R~ 
w E O N M T K K M V T O R T I S K K K O R L N K R S Y L I R R L T L N T M T K D R E ( 2 9 2 )  
mE 
790 750 770 790 810 890 
mE 
eL RGR~T~RRTTRRR~R~RRGR~CRRTT6CRRCR~TRT~R~RT~RGR6~TTC~T~TRcTTT6TC~RRRcRCTR~R~RR~TRTTT~TGR~RR~cTT~RR~R~T~T~TTCC~ 
e E R G K L K R R R I R T P G M O I R G F U Y F U E T L R R S I C E K L E O S G L P ( 2 7 2 )  
mE 
850 870 890 810 990 950 
mE 
=E ~TT~R~TRRT~R~RR~RR~TRRR~T~RRRTGTT~T~R~RRRT~RT~R~TRRTT~R~RR~R~RCR~R~TCTCTTT~R~RRTTR~T~6R~R~RRTR~RRRT~GRRT~R~RRT 
u E U G G N E K K R K L R N U U R K M M T N S Q D T E L S F T I T T B N T K N N E N ( 9 1 2 )  
mE 
970 990 1010 1090 1050 1070 
mE 
eL CRRRRTC~TC~RT~TTCCT~CGR~RT~cRTRCRT~RCRR~RRRTC~C~T~RRTG~TTTR~RRRC~TcCTGRG~RTc~cR~TRTRRT~TTcTCRRRTRRRRT~cRR~RCTRG~ 
u E O N P R M F L R M I T Y I T R H O P E N F R N V L ,  S I R P I M F S N K M R R L G (  5 2 )  
mE 
1090 1110 1190 1150 1170 1190 
mE G 
ut RR~GRTRCRT~TTC~RRRG~RR~RTGR~T~GRRCR~RRRTR~CR~RGRR~T~T~RR~TRTTGRC~TGRRRTR~TTTRRTGRRTCRR~RR~RRRGRRRRTCG~RRRRTR 
wE K 8 Y M F K S K 5 M K L R T 0 I P R E M L R 5 I B L K Y F N E 5 T R K K I E K I(992) 
mE E 
1210 1290 1250 1270 1290 1910 
mE 
uE R~C~TCT~TRRTR~RTG~R~RGT~T~RTT~RGT~TGG~TGRT~RTG~G~RT~TT~RR~RT~TRR~TR~RGT~RGGR~TCT~RRTCCTGRRTCTTGGR~R~RGRR~TR~R~ 
uLR P L L I D G T U S L 5 P G M M M 6 M F N M L S T U L G V S I L N L 8 0 K K y T(492) 
mE 
1990 1950 1970 1990 1410 1490 
mE T 
uE ~ R ~ C ~ T R ~ T ~ T ~ G ~ G G ~ T ~ R ~ T ~ T ~ T ~ T ~ C T T ~ C ~ T c R T ~ G T ~ T ~ c ~ R T ~ R T G ~ 8 ~ T R c ~ G c ~ G 8 ~ T ~ G ~ T R ~ R T T ~ T ~ R ~ R ~ C C T 8 ~ R R ~ C T R  
w E K T T Y W W O ~ L Q S S D O F R L I V N R P N H E G I Q R 6 U O R F Y ~ T C K L ( 4 7 2 )  
mE D 
1450 1470 1490 1510 1590 1550 
mE 
uE ~T~RRT~RTRT~R6~RRRRRGRR~TCCTR~RTRRRTR8~R~R~RCRTTT6RRTT~R~RRG~TTTTTCT~T~TRT~RTTT~TR~C~RTTTTR6~RTG~R~TG~cCR~TTT 
u E V G I N M S K K K S Y I N R T G T F E F T S F F Y R Y G F V R N F S M E L P S F ( 5 1 2 )  
mE 
1570 1590 1610 1690 1650 1670 
mE 
uL ~RGT8T~T~RRTTRRT~R~Tc~RTRT~R~CRTT~TRR~R~T~RTRRR~RRCRR~RT~RTRRR~RRT~R~TT~GG~R~c~R~c~cRR~T~cTCTTcRR~TRTT~RTc 
w E G U S G I N E S R D M S I G U T U I K N N M I N H O L G P R T R O L R L O L F I ( 5 5 2 )  
mE 
1690 1710 1790 1750 1770 1790 
mE G 
wE RR~TR~RGRTRTR~TR~GT~CC~R~R~G~GR~RCR~RRRTT~RG~RR~R~T~RTT~GR~TRRRGR~G~T~TG~R~RRR~C~T~RRR~CRG~R~TTTT~TTT~ 
wE K 0 Y R Y T Y R C H R 8 D T 0 1 0  T R R S F E L k K L H E 0 T R S K R G L L V S(592) 
mE G 
1810 1890 1850 1870 1890 1910 
mE 
wE ~RT~G~GGR~RRR~TTRTR~RT~G~T~T~R~RTT~CRGR~TCT~TTgR~TGGG~8~T~RTG~RT~RG~CTRTCR~8~R~TTT~TR~TC~TGRRT~RTTTGT~ 
wE 0 G G P N L Y H I R N L H I P E V 0 L k N E L M 0 E 0 Y 0 8 R L C N p L N p F V(692) 
mE 
1990 1950 1970 1990 2010 2090 
mE R T 
uE RGT~RTRR~R~RTT~R~T~TGTRRR~RRT~T~TRRT~CR~T~R~T~RGC~RR~RG~RTGG~TRT~RT~CT~TT~CTR~TR~R~R~T~CT~RT~TRR~R~6RR~CGc 
= E S H K E I E S U N N R U U M P R H G P R K S M E Y D R U R T T H S H I P K R H R ( 6 7 2 )  
mE T 
2050 2070 2090 2110 2190 2150 
mE 
uE T~TT~T~R~RR~RRR~G~TT~TT~R~RTG~RG~T~TRT~RG~GT~TT~RRTCTRTT~RGRR~TT~TT~T~CR~TT~TRCR~R~RC~R~TTGGR~TTT~ 
u E S I L N T S O R G I L E O E Q M Y Q K C C N L F E K F F P S S S y R R p U G I 5 ( 7 1 2 )  
mE 
2170 2190 2210 2290 2250 2270 
mE 
ut R~RT~TG~R~RT~GT~T~TR~GG~C~R~T~GRTTGR~TTCG~T~T~CG~RTTR~GRRR~RG~TT~TGR6RT~RT~RR~RT~T~TT~C~RTTGRRG~G 
uE S M U E R M U 5 R R R I D R R I D F E S 6 R I K K E E F R E I M K I C 5 T I E E(752) 
mE 
2290 2310 2398 
mE 
=E CTCRGRCGGC~RRRTRGTGRRTTTRGCTTGTCCTTCRTGRRRRRRTGCCTTGTTTCTRCT 
uk L ~ R 0 K(757) 
mE 
FIG. 5. Nuc leo t i de  and  pro te in  s e q u e n c e s  of  RNA s e g m e n t  2 o f  the  A/Ann/Arbod6/60 w t  and ca mu tan t  v i ruses.  C o m p l e t e  s e q u e n c e s  are 
s h o w n  fo r  the  w t  v i ruses.  Nuc leo t i de  c h a n g e s  d e t e c t e d  in the  m u t a n t  RNA are s h o w n  a b o v e  the  w t  s e q u e n c e ,  wh i l e  p red ic ted  a m i n o  acid 
c h a n g e s  in the  m u t a n t  are s h o w n  b e l o w  t he  w t  s e q u e n c e .  
562  
10 30 . 50 ~ 90 II0 
m~ 
u~ RGCGRRRGCRGGTC~RTTRT~TTC~TRTGGRRR~RRT~RRG~CTRC~TCTGRT6TC6~GTCTC~CRCTCGC~RGRTRCTRRC~RR~CCR0RGTG~RCCRTRTGGCCRT~RTT 
ut M E R I K E g R N L M S 0 S R T R E I L T K T T V 0 H M R I I(311 
mt 
130 150 170 190 210 ~0 
mL 6 
ut RR0R~GTR~RCRTCRGG8RGRCRG~RRRGRRCCCGTC~CTTRG~RT~RT~RTGRTGGCRRT0RRRTRTCC~R~RCRG~C8~CRRGRGGRT~RCR~RRRT~R~CCTGR~R~RRRT 
w~ K K y T S G R 0 E K N p S L R M K N M M R M K Y P I T R 0 K R I T E M I P E R N(711 
mL 
250 270 290 310 330 350 
mt 
wE ~0~RGG~C~RRCT~TRT~GT~RRRTGR~T~RTGCC~GRTCG~RTCGTGTG~TG~T~TC~CT~T~GCTGTG~RTGGT~6RRTRGRRRTGG~RT~RRGTR~G~CRTTRT 
wE E 8 G 0 T L N 3 K H S O R 6 5 0 R V M V S p L R V T N N N R N G P M T 5 T V H Y(I111 
mt 
370 390 410 430 4 ~  470 
mt 8 
wfi CCR~RRT~TRCRRR~R~GRGRRRGTC~RRRG8TTRRRRC~TG~RRCCTTTG~CCCTG~RT~TR~R~RRGTCRRRRTR~G~CGRRGR~GRCRTRRRT~T~GT~T 
wkp K i y K T y F E K V E R L K H G T F 6 P V H F R N 0 V K I R R R V 0 I N P G H11511 
m~ 
490 510 ~0 550 ~0  590 
m~ 
w~ G~RGRC~TCRGTG0CRRGGRGGCRCRGGRTGTRRTCRTG~R~TT~TTTTC~CTR~CGRRGT~G~GC~RTRCTRRC0TC~GRRTCGCRRTTRR~RTR~CCRRRGRGRRRRR~R 
u~R 0 L S R K E R 0 0 V I M E V V F p N E V 8 R R I L T 5 E S 8 L T I T K g K K E(1911 
mk 
610 630 ~0 670 690 710 
mt 
ut GRRCTCC~GRTT~CRRRR~TCRCC~T~RTGGTTGC~TR~RTG~G~RGRGRRCTT~TC~RRR~GRGR~TCT~RGTTGCTGGTGGR~C~GC~GTGTGTRCRTC~GT~ 
~t E L 0 0 C K i 5 p L M V R y M L E R E L U R K T R F L P V R G 0 T S ~ V Y I E V(2311 
mE 
730 750 770 790 810 830 
mt 
wt ~GCRC~RCTCRR8GRRCRTGCTG~G~CR~RTGT~CRCTCCR~GTG~RRGTGRG~RRTG~T~RT~RTCR~GTCT~R~RTT~RGCCRGGRRC~TRGTGRGRRGRGCRG~ 
ut L H L T 0 0 T C W E 0 M y T p G G E V R N 0 D V D 0 S L I I R R R N I V R R R R(2711 
850 870 890 910 930 950 
m~ 
w~ GTRTC~RGRT~CR~TR~RTCT~RTTG~RGRTGT~CR~RG~R~RGRTTGGCG~GR~RRG8RTGGT~GRCR~CTTRGGCRGRRc~RRCR~RRGRGCRRG~TGT~GR~RTRTGC 
w~ V S R 0 p L R 0 L L E M C H S T D I G 8 T R M V 0 I L R 0 N P T E E ~ R U E I 0(3111 
mt 
970 990 1010 1090 1050 1070 
mL 
w~ RRRG~TGC~RTG~GRCTGRG~RTC~CTCR~C~CR~T~TG~8~CR~TRRGR~RRCRRGC~GRTCRTCRGT~P~R~RGR~RGR~6TGC~CG~GCRRTCTTCRR~R 
wk K R R M G L R I S 5 S g S g 6 0 F T F K R T S G S S V K R E E E U L T G N L 0 T(3511 
m~ 
1090 1110 I I ~  1150 1170 1190 
mk T 
wE TT~RRRRTRR~GTGCRTGRG~GRTRC0RG~RGTT~RR~GGRF~R~G~RRCRGCTRTR~TCRG~R~GCRRCCRGGRGRTT~R~CR~CTGRTRGT~RGT0GRR~R~RCGRR 
wt L K I R V H E B y E E F T N V 6 K R a T R I L R K R T R R L I 0 L I V s G R 0 E{391) 
mt 
1210 I ~ 0  1250 1270 1290 1310 
mt T 
wt ~R~TC~RTR~CCG~CRRTRR~TGGCC~T~TRTTTTCR~R~RRGR~TRT~RTRRRF~GCRGTTF~0TGRTCTGRR~TC~TTRRTRG~G~RRRTC~GC~R~GRRT~RTG 
wk 0 S I R E R I I V R M V F S O E 0 C H I K R V R G 0 L N F V N R R N D R L N P M(4311 
mk 
1330 1350 1370 1390 1410 1430 
mt 8 
uE C~TCR~C~TT~G~CRTTTT~G~A~GATGCTRRF~T~TTTTT~A~GG~R~G~CAT~TC0~T~TGA~G~R~TG~8G~GT~TT~GR~T~CTCCA~P~ 
wk H Q L L R H F 0 K 0 R K V L F 0 N N 0 I E H I 0 N V N 0 M 1 8 V L P 0 M T P 5 T(4711 
mk 
1450 1470 1490 1510 1530 1550 
wE GR~RT~TC~TGRGRG~GGTRR~R~TCRGC~R~T~GG~T~RTG~T~TCCRGC~C~RGRGRGTRGTG~TGRGCR~GR~80TTTTT~G~8RG~CCRF~RGG~T8TR 
w~ E N 5 M R G V ~ V 5 K M G V D E Y S S R E R V U U S I 0 R F L R V R D Q R 0 N V(5111 
i ~ 0  1590 1610 I ~ 0  16~ 1870 
m~ 
uk CTRCTRTCT~T0~G8RG8~RGTGRRRCRCRGGGRRCRG~P~TGRC~T~R~TT~T~T~GTCRRT~TGT~GGRGRTTRRTC~.~CTGRGTCRGTGTTGGT~RTR~CTRTCRG 
wkL L S P E E U 3 E T Q 6 T E K L T I T Y S S 5 M M H E I N G P E S V L V N T Y 0(5511 
mE 
1690 1710 1730 I~0 1770 1790 
mt 
wE TGG~TCATC~R~TG~0~cT~R~TTCAGT00TcTc~G~T~CT~C~TGcT~TRc~TR~RATG8~TG~G~TTr~GT~T~-[AGTTCcTR~TT~0~R~ 
~E W I I R N N E T V K I O N ~ 0 N P T M L Y N k M E F E P F O ~ L V P K R I R 0 0(5911 
m~ 
1B10 1830 1850 1870 1890 1910 
m~ 
w~ T~R0TGGG~T~TTR8G~CT~T~TTCc~RC~RRT8RG0~RTGTRc~G0~RT~G~TRCCRcc~GRT~T~R~cTT~TT~ccT~Gc~Gc~G~ccc~8c~RRGTRG~TG 
wE Y 5 G F V R T L F Q 0 M R D V L G T F 0 T T G I I K L L P F R R R P P K 0 G R M(6311 
mE 
1930 1950 1970 I990 2010 2030 
mk G 
wt C~R~TC~CR;T~R~TGT~RTGTG~G~TC~8RR~RG~T~C~GTRRG~G~CP~CT~TRT~TTCRRCTR~R~C~NR~CRCT~R~CT~TTCTCG~R~:~GG~T 
wt 0 F S S L T V N V R G S G H R I L V R G N S P I F N Y N ~ T T K R L T I L G K 8(6711 
mt 
2050 2070 2090 2110 2130 2150 
mE 
wE ~T~R~T~R~CT~RGRC~CRG~TG~GG~RT~TGGR~T~G~T~C0CTG~T~GR~CCTC~CT~GG~RGRRGRT~GGRG~TRTG~RCCR~R~G~T~RT 
wE R G T L T E 0 P 0 E G T 5 G V E S R V L R 0 F L I L 0 K E 0 R R Y G P R L 5 1 N(7111 
mt 
2170 2190 2210 2290 2250 2270 
mE 
~ T G R 0 T R R C ~ T T ~ G ~ R G G R G ~ G ~ C T ~ T ~ T ~ C T ~ T T G ~ C ~ G R ~ T ~ G G T R R T G R R ~ G R R R R ~ C T ~ T ~ R T R C T T ~ C T G R ~ R G ~ G ~ G R ~ C  
u E E L S N L R K G E K R N V L I G S ~ O U V L U M K R K R N S ~ I L T O S Q T R T ( ( 7 5 1 1  
mE 
~ 9 0  2310 ~ 3 0  
mE 
~RASGRTTCGGRTGGCCRTCRR~RRTG~G~TRGT~RRRRRCGRCC~GTTTCT~T 
wE K R I R M R I N(7591 
mt 
FIG. 6. Nuc leo t i de  and pro te in  s e q u e n c e s  of  RNA s e g m e n t  1 o f  the  A / A n n / A r b o d 6 / 6 0  w t  and ca mu tan t  v i ruses.  C o m p l e t e  s e q u e n c e s  are 
s h o w n  fo r  the  w t  v i ruses.  Nuc leo t i de  c h a n g e s  d e t e c t e d  in the  mu tan t  RNA  are s h o w n  above  t he  w t  s e q u e n c e ,  wh i l e  p red ic ted  am ino  acid 
c h a n g e s  in the  m u t a n t  are s h o w n  b e l o w  the  w t  s e q u e n c e .  
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TABLE 1 
SUMMARY OF COMPARATIVE SEQUENCE DATA FOR A/Ann Arbor/6/60 WILD-TYPE AND MUTANT VIRUSES 
RNA 
segment 
Nucleotide change Position changed 
No. of changes wt MT Nucleotide a.a. 












1 Coding change AAC AGC 821 
4 Noncoding changes AG_A AGG 141 
G~-_ GTC 426 
ATA A-I~_ 1182 
GCC GOT 1212 
GCT GCG 1353 
CA-A CAG 1923 
4 Coding changes AAA G_AA 1196 
GAG GAT 1395 
GAG GGG 1766 
GCT ACT 2005 
3 Noncoding changes GGA GGG 123 
GGC GGT 486 
TC_C_ TCT 2019 
2 Coding changes AAG GAG 1861 
FI-A C__C_A 2167-8 
1 Noncoding change T C_ 20 
2 Coding changes ACT A-AT 
GAT GGT 
Single nucleotide GAAAAAT GAAAAA-AT 
insertion 
1 Coding change GOT 3-CT 
1 Coding change GCG -ACG 







265 Asn Ser 
391 Lys Glu 
457 Glu Asp 
581 Glu Gly 
661 Ala Thr 
613 Lys Glu 
715 Leu Pro 




- -  r 
Ala Ser 
Ala Thr 
total number of nucleotide or amino acid changes ac- 
quired during attenuation represents less than 1% of 
the genome or protein in each case (reviewed by Co- 
hen et al., 1987). There are more differences between 
wt and ca A/Ann/Arbor/6/60 viruses than between wt 
and vaccine strains of poliovirus 3 but fewer differ- 
ences than between wt and vaccine strains of poliovi- 
rus 1, yellow fever virus, hepatitis A virus HM-175 (Co- 
hen et aL, 1987), and influenza B viruses (DeBorde et 
aL, 1988). It seems clear that relatively few changes 
are present in a variety of attenuated RNA viruses. Be- 
cause viral RNA genomes are extremely heteroge- 
neous (Domingo et al., 1985), sequencing of a viral 
RNA template results in a consensus sequence con- 
sisting of the base present at the greatest frequency at 
each nucleotide position. Sequence variations present 
in minor subpopulations remain undetected. These low 
frequency sequence variations, however, would not be 
expected to contribute significantly to the phenotypic 
properties of the virus. 
During the many clinical studies conducted with in- 
vestigational ca vaccines derived from the ca A/Ann Ar- 
bor/6/60 virus, over 900 isolates from human volun- 
teers have been tested for the phenotypic properties 
of cold-adaptation and temperature-sensitivity, and no 
true revertants have been detected (Murphy et aL, 
1980; Wright etaL, 1982; Maassab, personal commu- 
nication). Similarly, reversion has not been demon- 
strated in ferrets (Maassab et al., 1982). This is in con- 
trast to results with investigational ts influenza live at- 
tenuated vaccines (Murphy et aL, 1 980; Tolpin et al., 
1981). It is likely, therefore, that more than one of the 
mutations identified here are biologically important, so 
that if reversion or suppression of one mutation occurs, 
attenuation conferred by other independent muta- 
tion(s) remains. This is supported by data obtained with 
single gene reassortants (Snyder et al., 1 987). Thus, 
all available data support the previous suggestion that 
candidate vaccine strains be selected on the basis of 
having six internal genes of the mutant donor parent 
since multiple mutations throughout the genome might 
confer increased stability (Cox etaL, 1 979, 1 986). 
Now that the precise nature of the mutations in the 
A/Ann Arbor/6/60 ca donor strain has been deter- 
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mined, it wou ld  be relatively simple to sequence rapidly 
the relevant areas of each gene in viruses prepared for 
human use or in viruses recovered from infected volun- 
teers to moni tor  the stabil i ty of these mutat ions during 
product ion and use of ca reassortant candidate vac- 
cines. This approach wou ld  not detect suppressor  mu- 
tat ions (Scholtissek, 1984), however, and monitor ing 
of phenotypic propert ies wou ld  also be important, 
Because it wou ld  be expected that a combinat ion of 
nonspeci f ic  mutat ions and mutat ions speci f ic for the 
phenotypic  propert ies of the ca A/Ann Arbor /6 /60 virus 
might occur  during the process of cold-adaptat ion, we 
have attempted to deduce the l ikel ihood that the muta- 
t ions detected are involved in the phenotypic  proper- 
t ies of the virus. After taking into considerat ion the 
available data, we suggest  that the changes in the ca 
A/Ann Arbor /6/60 virus that are of part icular interest 
for future study are as fol lows: (1) the alanine to serine 
change at amino acid 86 in the M2 protein, (2) the leu- 
cine to proline change at amino acid 71 5 in the PA pro- 
tein, (3) the asparagine to serine change at amino acid 
265 in PB2, and (4) any or all of the four changes in 
the PB1 protein. While it is useful to at tempt to identi fy 
those changes most likely to be involved in the pheno- 
typic propert ies of the ca virus, conc lus ions made at 
this t ime must be v iewed as prel iminary for the fo l low- 
ing reasons: (1) Some contradic t ions appear in results 
from genetic complementat ion or recombinat ion ex- 
periments that used different ts mutant  sets (Spring et  
aL, 1977; Reeve et  aL, 1980a; Cox et  al., 1981). (2) 
Conclus ions about the genetic basis of at tenuat ion 
made wi th single segment  reassortants may not apply 
for different wi ld- type parents. (3) Mix ing polymerase 
genes of two human inf luenza viruses may in itself at- 
tenuate a reassortant (Florent, 1 980). (4) Some of the 
mutat ions in the A/Ann Arbor /6/60 ca mutant  that are 
also present in other w t  sequences may be biological ly 
s igni f icant in the context  of other sequence changes. 
Experiments that use si te-specif ic mutagenesis and 
DNA expression systems to demonstrate the effect of 
a part icular mutat ion in a funct ional  assay as wel l  as 
exper iments to obtain and sequence phenotypic  rever- 
tants will be necessary to further define the biological 
importance of the mutat ions reported here. Until defin- 
itive studies are complete, it is advisable that, to mini- 
mize the risk of reversion to virulence, vacc ines used 
in open populat ions contain all genes except  those 
coding for HA and NA from the ca parent. 
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